Schizophrenia Clinical Trial
Official title:
Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
D2 dopaminergic receptor blockers, used to treat schizophrenia, can lead to the onset of movement disorders. Drug-induced movement disorders encompass several syndromes. Parkinsonism, dystonia, dyskinesia and akathisia are the most prevalent. All of them lead to poor adherence to the treatment instituted, decrease in the quality of life, relapses and hospitalizations. The pathophysiology of drug-induced movement disorders is complex and poorly understood, but seems to be associated with oxidative stress, as a result of an increase in free radicals generated from dopamine metabolism. Treatment strategies following the onset of drug-induced movement disorders include neuroleptic discontinuation, use of atypical antipsychotics and anticholinergics. A pre-clinical study showed that the antioxidant properties of vitamins B6 and B12, alone or in combination, prevented the development of orofacial dyskinesia induced by haloperidol. This clinical trial aims to evaluate the effects of vitamins B6 and B12 on the treatment of patients diagnosed with schizophrenia, schizoaffective or bipolar disorder who present with tardive dyskinesia, dystonia and parkinsonism.
D2 dopaminergic receptor blockers, used to treat schizophrenia, can lead to the onset of
drug-induced movement disorders, such as parkinsonism, dystonia, dyskinesia and akathisia.
They seem to be associated with oxidative stress, as a result of an increase in free radicals
generated from dopamine metabolism. A preclinical study showed that vitamin B6 (pyridoxine)
and B12 (cobalamin), alone or in combination, prevented the development of orofacial
dyskinesia induced by haloperidol in an animal model of schizophrenia.
Specific Aim1: To conduct a prospective, randomized, double-blind, placebo-controlled trial
to evaluate the efficacy of 12-week adjuvant treatment with 200mg of pyridoxine (B6) or 2mg
of cobalamin (B12) to treat drug-induced movement disorders of patients with schizophrenia,
schizoaffective or bipolar disorder. The investigators will randomly assign 45 patients into
three groups: placebo, B6 or B12 and check whether administration of vitamin B6 (pyridoxine)
or B12 (cobalamin) attenuates drug-induced movement disorders (IDDM) in patients with
diagnosis of schizophrenia, schizoaffective or bipolar disorder.
Specific Aim 2: To quantify changes in serum markers of inflammation and biomarkers of
oxidative stress in response to adjunctive treatment with B6 or B12. The hypothesis is that
changes in these biomarkers will mediate the clinical response to them.
Research Plan: The investigators will carry out a proof of concept 12-week prospective,
randomized, double-blind, controlled trial of vitamin B6 and B12, at doses of 200 mg/day and
2mg/day, respectively, or identical placebo tablets, added to ongoing antipsychotics in 45
stable patients (ages 18-60 years, 15 patients per group) with diagnosis of schizophrenia,
schizoaffective or bipolar disorder. The study will be conducted at the Drug Research and
Development Center (NPDM), at the Universidade Federal do Ceará, Fortaleza, Brazil. This
center has a long history of performing placebocontrolled trials in clinical medicine
(http://www.npdm.ufc.br/) and has the necessary infrastructure to successfully complete the
proposed study protocol. All participants will give written informed consent prior to study
enrollment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A | |
| Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 |